How to access Ubrelvy from Bahrain, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Bahraini patient who experiences disabling migraine attacks that are poorly controlled by, or contraindicated for, triptans may receive a prescription for Ubrelvy (ubrogepant) from their treating neurologist or headache-clinic physician. Ubrelvy is FDA-approved for the acute treatment of migraine with or without aura in adults. It is manufactured by AbbVie (Allergan) and was one of the first oral CGRP receptor antagonists approved for acute migraine. In Bahrain, Ubrelvy may not yet be broadly stocked through hospital formularies, which is why your neurologist may be navigating a named-patient import pathway with you.

This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.

The clinical situation

Ubrelvy is an oral tablet taken as a 50 mg or 100 mg dose at the onset of a migraine attack, with an optional second dose at least two hours later (maximum 200 mg in 24 hours). As a gepant, it provides a non-vasoconstrictor alternative to triptans, which makes it particularly useful for patients with cardiovascular disease, uncontrolled hypertension, or prior adverse triptan experience. It does not replace preventive therapy, that is a separate clinical decision. Your neurologist determines eligibility based on attack pattern, prior therapy history, and comorbidities.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Is Ubrelvy legally importable into Bahrain?

Yes, through the National Health Regulatory Authority (NHRA) named-patient framework, with parallel authority through DoH Abu Dhabi and DHA Dubai depending on the prescribing facility. The pathway allows a Bahrain-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally available alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.

For Ubrelvy specifically, the application is routine, an oral tablet with standard room-temperature handling and no REMS or cold-chain complexity.

How the pathway works, step by step

1. Consultation with your treating neurologist. Migraine diagnosis per ICHD-3 criteria, documentation of prior triptan trials or triptan contraindications, and the clinical rationale for a gepant.
2. NHRA / DoH / DHA named-patient application. Your physician files the application including clinical letter, patient identifier, and product details.
3. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure the product from the manufacturer's authorised distribution chain.
4. Shipment. Ubrelvy ships at controlled room temperature; no cold-chain is required.
5. Arrival and dispensing. The receiving facility dispenses per your neurologist's direction.

What documentation your physician needs

Your physician will typically need to provide:

• Clinical rationale letter confirming migraine diagnosis, attack frequency, prior triptan or other acute-therapy history, and Ubrelvy as the indicated acute treatment
• Verification of Bahrain medical licence
• Patient identifier
• Prescribed dose and projected monthly tablet count

Reserve Meds provides a physician documentation kit that bundles the templates NHRA reviewers expect to see.

Costs and timing

Ubrelvy's US cash-pay drug-only reference price sits in a broad indicative range, roughly USD 900-1,000 for a 10-tablet carton. Shipment, documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. Indicative range.

Indicative timing for the first dispensed supply after cohort intake opens is 14-21 days from the moment a complete application is submitted. Refills ship on a rolling basis once the pathway is established.

If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Ubrelvy specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for NHRA/DoH/DHA review.
• Logistics. Controlled-room-temperature shipment coordination.
• Concierge case lead. A named point of contact throughout.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

Frequently asked

Is this legal in Bahrain? Yes, when executed through the NHRA named-patient framework with appropriate documentation.

How is Ubrelvy different from Nurtec? Both are gepants. Ubrelvy is approved for acute migraine only; Nurtec is approved for both acute and preventive use. The clinical choice depends on whether you need rescue only, prevention, or both.

Can I use Ubrelvy alongside a preventive like a CGRP monoclonal? Yes, gepant acute therapy is commonly combined with preventive therapy (erenumab, fremanezumab, galcanezumab, eptinezumab, or atogepant) under neurologist supervision. The regimens are complementary.

Will private insurance cover this? Cash-pay is the default. Some Bahrain private insurers reimburse named-patient imports; we supply documentation for your submission but do not process insurance claims directly.

Next step

For Ubrelvy coordination in Bahrain, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.

Or download the PDF guide ›

---

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Clinical & regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-04-23.